STRO
Sutro BiopharmaANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
The bull case is that STRO-004 shows tolerable early safety and enough activity to support best-in-class TF ADC positioning, while Astellas milestones and 2028 runway reduce immediate dilution pressure and allow multiple shots on goal through 2026 [#8-K-2026-03-23].
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta -15.3.
What can break
Future capital needs remain significant despite runway extension
Momentum
84
Value
41
Sentiment
60
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $27.00 · Bull $38.00 · Bear $18.00
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-15 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $32.50
Why
Momentum84 · Δ7d -15.3
Value41 · Δ7d +0.1
Sentiment60 · Δ7d -7.3
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
84
34% active weight
Current posture
7d trendSoftening
Δ7d
-15.3
Δ21d
-16.9
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
60
33% active weight
Current posture
7d trendSoftening
Δ7d
-7.3
Δ21d
+34.1
Why this grade
Composite grade A. Momentum 84.3 / Value 41.1 / Sentiment 59.7
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$468.12M
Beta
1.55
Shares Out
8.52M
P/E (TTM) · Derived
-1.9
P/S (TTM)
0.88
P/FCF (TTM) · Derived
-2.04
Rev YoY
+13.8%
EPS YoY
-12.7%
Gross Margin
-
Op Margin
-175.7%
Net Debt
-$316.9M
Current Ratio
2.53
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology